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Prion diseases in humans and animals are due to con-
formational conversion of PrPC, a cellular glycoprotein
of unknown function, into PrPSc, an isoform that ap-
pears to be infectious in the absence of nucleic acids.
Proteins that behave as prions are also found in yeast
and filamentous fungi. Although there is now strong
experimental support for the hypothesis that prions
are infectious proteins, two subjects have remained
poorly understood: the structure of prions, and the
mechanisms by which they kill neurons. In this review,
we will highlight recent studies that shed new light on
these important issues.
Prion diseases, or transmissible spongiform encephalop-
athies, are fatal neurodegenerative disorders that have
garnered enormous attention from both scientists and
the public. These disorders include Creutzfeldt-Jakob
disease and kuru in humans, as well as scrapie and bovine
spongiform encephalopathy in animals. They are charac-
terized clinically by dementia and motor dysfunction, and
neuropathologically by spongiosis, amyloid deposition,
and neuronal loss. Prion disorders havebeenofenormous
concern from a public health standpoint because of the
epidemic spread of bovine spongiform encephalopathy
and its transmission to human beings as a variant form
of Creutzfeldt-Jakob disease.
A prion is defined as an infectious protein. A wealth of
evidence suggests that the central molecular event in
prion diseases is the conformational conversion of PrPC,
a normal cell-surface glycoprotein, into PrPSc, an abnor-
mal isoform that is infectious in the absence of nucleic
acid (Prusiner, 1998). PrPC is largely a-helical, mono-
meric, and protease sensitive, while PrPSc is rich in b
sheets, aggregated, and protease resistant. Prion prop-
agation is thought to involve a templating mechanism
in which PrPSc seeds conversion of PrPC substrate in
an autocatalytic fashion. Prion diseases thus exemplify
a novel mechanism of biological information transfer
based on self-propagating changes in protein conforma-
tion, rather than inheritance of nucleic acid sequence.
Prions have also been described in yeast and other
fungi, and studies of these more experimentally tractable
organisms have provided powerful insights into prion bi-
ology (Shorter and Lindquist, 2005). [PSI+] and [URE3],
the two most well-studied prions in Saccharomyces
cerevisiae,arecomposed,respectively,ofSup35p,atran-
slation termination factor, and Ure2p, a transcriptional
regulator involved in nitrogen metabolism. The prion
found in the filamentous fungus Podospora anserina,
designated [Het-s], is derived from the HET-s protein,
which plays a role in heterokaryon incompatibility.
*Correspondence: dharris@wustl.eduEach of these proteins can exist in two alternate confor-
mational states, with one state capable of imprinting
its conformation on the other via cytoplasmic mixing or
mating. Experiments on yeast and fungi have allowed
more direct tests of hypotheses concerning protein-
only transmissibility, species and strain barriers, and
the role of molecular chaperones than has been possible
in mammalian systems. In addition, these studies have
led to the important conclusion that prions are not neces-
sarily deleterious; indeed, they can be agents of pheno-
typic variation and evolutionary change (True and Lind-
quist, 2000), and it has been proposed that they play
a role in memory storage (Shorter and Lindquist, 2005).
It seems likely that additional prions will be discovered
in mammals and other organisms and that the prion phe-
nomenon will turn out to be quite general in nature.
When first proposed almost 25 years ago, the prion
hypothesis was greeted with intense skepticism. Now,
there is a large body of compelling evidence that this
idea is correct. Perhaps the most definitive experiments
involve generation of synthetic prions in the test tube.
Purified, recombinant Sup35p, Ure2p, and HET-s can
be polymerized in vitro and introduced into susceptible
yeast or fungal cells to produce self-propagating pheno-
typic changes (Shorter and Lindquist, 2005). Production
of infectious mammalian prions has also been reported
recently, either by polymerization of recombinant PrP
(Legname et al., 2004) or by PrPSc-catalyzed conversion
of brain-derived PrPC in a cyclic amplification process
(Castilla et al., 2005). Although subject to some criticisms,
these experiments have gone a long way toward dem-
onstrating the protein-only mechanism of prion trans-
mission.
Although we now know a great deal about prions and
the mechanisms by which they propagate, two critical
subjects have remained poorly understood: the physical
structure of prions and the mechanism by which they
cause pathology.
The Structure of Yeast and Other Fungal Prions
Although amyloid fibers are difficult to detect in yeast
and Podospora cells, several lines of evidence support
the notion that amyloid fibers polymerized in vitro from
purified Sup35p, Ure2p, and HET-s are representative
of prion structures found in vivo. Most notably, the fibers
are able to ‘‘infect’’ yeast or Podospora and confer the
prion state. Several recent studies of these amyloid
forms have provided new insights into the structure of
infectious prions, the process of self-assembly, and the
origin of prion strains. The results have broad implica-
tions for prion biology, amyloid-related diseases, and
principles of protein structure.
In the first study, Nelson et al. (2005) carried out X-ray
crystallographic analysis of amyloid polymers of a pep-
tide derived from the N-terminal, prion-forming domain
of Sup35p. The deduced structure consists of a pair of
b sheets running parallel to the fiber axis and bonded
together by interdigitating side chains that form a dry,
self-complementary interface referred to as a steric zip-
per. The b strands in each sheet run perpendicular to the
fiber axis and are held together by hydrogen bonds
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structure is common to other kinds of amyloid fibrils,
all of which display a cross-b diffraction pattern. Many
proteins, regardless of whether they are associated with
protein-misfolding diseases, have the capacity to form
amyloid fibrils under suitable conditions, and it has
been suggested that this is a generic property of all poly-
peptide chains (Dobson, 2003).
In a second study, Ritter et al. (2005) used NMR spec-
troscopy and fluorescent probe accessibility to deter-
mine the structure of amyloid fibrils formed from a frag-
ment of the HET-s protein. The basic structural unit was
remarkably similar to that determined for the fibrils of
Sup35p peptide, consisting of two interlocking b sheets,
although in this case each HET-s molecule contributed
two adjacent b strands in each sheet. In a truly elegant
series of experiments, these authors went on to show
that proline substitutions that disrupted the amyloid
core structure also abolished the infectivity of the HET-s
fibrils when tested in biological assays in Podospora. In
contrast, structurally nondisruptive substitutions did
not affect infectivity. This satisfying correlation provides
strong evidence that amyloid fibrils represent the infec-
tious form of prions and that prion propagation is likely
to involve seeded polymerization of these fibrils.
In a third study, Krishnan and Lindquist (2005) em-
ployed a variety of chemical techniques to analyze the
structure of amyloid fibrils assembled from a fragment
of Sup35p containing the N-terminal (N) and central (M)
domains of the protein. They suggest a model in which
the N domain consists of head, central core, and tail
regions, with the amyloid fiber formed by head-to-head
and tail-to-tail contacts between subunits. Their data
also suggest that the critical nucleation step of polymer
assembly is the result of an initial interaction between
the head regions of individual subunits.
The study by Krishnan and Lindquist also illuminates
another contentious subject in the prion field: prion
strains. In mammals, prion strains are defined as infec-
tious isolates that produce distinct incubation times
and patterns of neuropathology when inoculated into
a standard host (usually an inbred mouse) (Prusiner,
1998). For viruses or bacteria, strains are the result of
variations in the nucleic acid genomes of the infectious
agents. Since prions lack nucleic acid genomes, the
best way to explain prion strains is to postulate that
they result from variations in protein conformation. Con-
sistent with this hypothesis, different strains of PrPSc are
known to display distinctive biochemical signatures
(e.g., glycosylation pattern, protease cleavage site).
Strains of yeast prions can also be distinguished, based
for example on strength of nonsense suppression (for
Sup35p), mitotic stability, or aggregation state of the
corresponding protein (Shorter and Lindquist, 2005).
Until recently, however, there was no direct evidence
that the three-dimensional structures of individual prion
strains differed from each other.
To address this issue, Lindquist and Krishnan ana-
lyzed the structures of two strains of Sup35p NM amy-
loid, produced by assembly at different temperatures
(4ºC and 25ºC), which create different [PSI+] phenotypes
when introduced into yeast. These two forms were found
to differ in the length of the amyloid core region as well as
in the nature of the interfaces between subunits. Theseresults are remarkably similar to those obtained by Ta-
naka et al. (2005), who analyzed three different Sup35p
strains using electron paramagnetic resonance. In a re-
cent study that underscores the parallel between mam-
malian and yeast prions, it was reported that a truncated
form of PrP (23-144) could be polymerized in vitro into
two kinds of fibers with distinct morphologies and spec-
troscopic signatures; in this case, the nature of the seed
used to initiate the polymerization reaction determined
which of the two fiber variants was produced (Jones
and Surewicz, 2005). Interestingly, self-propagating
structural polymorphisms have also been described in
fibrils assembled from Ab, the protein subunit of amyloid
plaques in Alzheimer’s disease, raising the possibility
that strain variation may be characteristic of non-prion
amyloids as well (Petkova et al., 2005).
The Structure of Mammalian Prions
The three-dimensional structure of PrPC, determined by
NMR spectroscopy and X-ray crystallographic analysis
of recombinant and brain-derived PrP, consists of a dis-
ordered N-terminal region (residues 23–124) and a C-
terminal region (residues 125–228) composed of three
a helices and two short b strands flanking the first a helix
(Zahn et al., 2000). The structure of PrPSc has been much
more difficult to determine. It is clear that the two iso-
forms are very different at the level of secondary struc-
ture, with PrPSc having a much higher proportion of
b sheets than PrPC (45% compared with 3%) (Prusiner,
1998). However, it has not been possible to resolve the
tertiary structure of PrPSc, largely because of the ten-
dency of the protein to form large, heterogeneous ag-
gregates that are recalcitrant to analysis by high-resolu-
tion techniques. The aggregation tendency of PrPSc
reflects the intrinsic nature of the PrPC-PrPSc conversion
process, which has properties of a seeded polymeriza-
tion. Thus, a monomeric form of PrPSc is unlikely to exist.
Electron microscopic analysis of two-dimensional crys-
tals of PrP 27-30 (a proteolytic fragment of PrPSc) in con-
junction with theoretical considerations has led to a
model of PrPSc that is based on stacked, left-handed
b helices (Govaerts et al., 2004). However, other models
have also been proposed, based on computer modeling
or on structural analysis of recombinant PrP or synthetic
PrP peptides that have been induced to adopt b-rich
conformations (see, for example, Lee and Eisenberg,
2003).
One structural issue that has received considerable
attention concerns the oligomeric structure of infectious
PrPSc. The main approach to this problem has been to
dissociate highly infectious PrPSc using various deter-
gents and chaotropic agents and then test the infectivity
of the resulting PrPSc oligomers, either by animal bioas-
say or by an in vitro conversion assay. The primary con-
clusion from this work has consistently been that infec-
tivity resides in oligomeric and not monomeric forms of
PrP. In a particularly rigorous new study, Silveira et al.
(2005) have characterized the biophysical properties of
partially disaggregated PrPSc samples using chromato-
graphic size fractionation. These authors conclude that
the greatest infectivity (per unit mass of PrP) is associ-
ated with particles having an average size of 17–27 nm
(300–600 kDa) and consisting of 14 to 28 PrP molecules.
Much less specific infectivity was associated with mo-
nomeric PrP or large fibrils. A major implication of this
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fectious than highly polymerized amyloid rods, and
therefore attempts to limit prion propagation by break-
ing up PrPSc aggregates may actually have the opposite
effect.
Considerable evidence indicates that prion propaga-
tion in both fungi and mammals has the characteristics
of a nucleated polymerization reaction. For yeast and
other fungal prions, the evidence is quite strong that
polymerization results in an amyloid fibril structure that
is correlated with infectivity (Ritter et al., 2005; Tanaka
et al., 2005). For mammalian prions, the structural data
are more equivocal. Certain forms of purified, recombi-
nant PrP polymerize into amyloid fibers in vitro (Baska-
kov, 2004; Jones and Surewicz, 2005). However, in only
one case has it been shown that these synthetic fibers
are infectious in animal bioassays (Legname et al.,
2004), and in that study the infective titer was low, imply-
ing that only a small subset of molecules possessed
a conformation capable of self-propagation. It has also
been surprisingly difficult to visualize PrP fibrils in brain
tissue, and many cases of human and animal prion dis-
eases lack cerebral plaques that stain with amyloid-
specific dyes. Thus, there is continuing debate about
whether infectivity is associated with amyloid forms of
PrPSc, or with other kinds of b sheet-rich, oligomeric
structures (Wille et al., 2000). In the study of Silveira
et al. (2005), EM analysis of the most infectious PrPSc
fractions revealed small amorphous aggregates lacking
the features of amyloid fibrils and without clearly defined
ends. Failure to demonstrate amyloid fibrils either in situ
or in purified fractions may be due to the fact that these
structures are below the resolution limit of the electron
microscope or because they are disrupted by the
methods used for tissue preservation or protein extrac-
tion. It is also possible that cellular factors such as mem-
brane tethering or protein degradation restrict the size
of fibrils or modify their morphology in an in vivo setting.
Alternatively, there may be fundamental differences be-
tween fungal and mammalian prions in the structure of
the replicating unit, with mammalian prions propagating
via nonamyloid conformations.
A number of human diseases are characterized by the
deposition of intracellular or extracellular protein aggre-
gates in either the CNS or peripheral tissues. These in-
clude other neurodegenerative disorders like Alzheimer’s,
Parkinson’s, and Huntington’s diseases, as well as a
number of systemic amyloidoses. In many of these cases,
the protein component of the deposits polymerizes into
fibrils that display the cross-b structure characteristic
of amyloids (Dobson, 2003). Since all of these amyloid-
genic proteins are capable of self-seeded assembly,
at least in vitro, why is it that only prion diseases are
transmissible in vivo? Possibly, localization of some of
the proteins in intracellular compartments may render
them inaccessible for transfer between cells. Cellular
processes such as posttranslational modification or
degradation might also reduce infectious transfer. In
summary, then, not all amyloids are prions (i.e., are infec-
tious), and not all infectious proteins (prions) are neces-
sarily amyloids.
What Is the Neurotoxic Form of PrP?
Historically, a great deal of effort in the mammalian prion
field has been devoted to defining the chemical nature ofthe infectious agent. In contrast, much less is known
about the cellular mechanisms by which prions kill neu-
rons and the toxic forms of PrP that are responsible.
While it has commonly been assumed that PrPSc itself
is the primary cause of neurodegeneration in prion dis-
eases, this assumption is based primarily on the temporal
and anatomical correlation between the accumulation
of this form and the development of neuropathological
changes. However, there are a number of situations
where this correlation is weak or absent (Chiesa and
Harris, 2001). In several kinds of transmission experi-
ments, for example, significant pathology and/or clinical
dysfunction develop with little accumulation of PrPSc.
Conversely, there are subclinical infections in which
there is abundant PrPSc but little symptomatology.
Taken together, these results argue that PrPSc, the infec-
tious form of PrP, may not be the proximate cause of neu-
ronal dysfunction and degeneration in prion diseases.
What is the identity of PrPtoxic, the neurotoxic species?
Several candidates have been proposed, each of which
is thought to be pathogenic but not infectious. For exam-
ple, transmembrane and cytosolic forms of PrP (CtmPrP
and CytoPrP, respectively), which differ from conven-
tional PrP in their membrane topology, each cause a
neurodegenerative illness without accumulation of PrPSc
when expressed in transgenic mice (Ma et al., 2002;
Stewart et al., 2005). PrP is normally tethered to the
outside surface of cellular membranes via a glycosyl-
phosphatidylinositol (GPI) anchor, which is a lipid- and
glycan-containing structure that is added to the C termi-
nus of the polypeptide chain during synthesis in the ER.
In contrast, CtmPrP spans the lipid bilayer once via a con-
served hydrophobic segment, with the N terminus on the
cytoplasmic side. CytoPrP lies entirely in the cytoplasm
and arises from abortive translocation or reverse translo-
cation of the polypeptide chain at the ER. Both of these
forms may be neurotoxic because they interact abnor-
mally with membranes or with cytoplasmic proteins to
which the PrP polypeptide chain is not normally ex-
posed. Although CtmPrP and CytoPrP cause neurodegen-
eration when expressed at elevated levels in transgenic
mice, it remains to be proven that these species accumu-
late naturally during the course of a prion infection.
Additional insights into the nature of PrPtoxic have de-
rived from transgenic mice that express mutant forms
of PrP associated with familial prion diseases. Mice ex-
pressing a mutant PrP molecule with octapeptide inser-
tion found in some cases of familial Creutzfeldt-Jakob
disease spontaneously develop a fatal neurodegenera-
tive disorder accompanied by accumulation of a weakly
protease-resistant, noninfectious form of the mutant
protein (Chiesa et al., 2003). Biochemical characteriza-
tion of this form demonstrates that it consists primarily
of small oligomers of conformationally altered PrP, in
contrast to the larger, more tightly packer polymers of
PrPSc. Thus, the biophysical properties of infectious
and toxic forms of PrP may differ, with the latter being
less highly polymerized. Similar conclusions have been
reached in a recent study of transgenic mice that
express PrP carrying a point mutation linked to
Gerstmann-Stra¨ussler syndrome, an inherited prion dis-
order (Nazor et al., 2005).
A recent study by Chesebro et al. (2005) sheds new
light on the molecular features that are required to
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mice that express a form of PrP that is lacking the GPI
anchor. This was accomplished by deleting the C-termi-
nal signal for anchor attachment. Amazingly, when these
mice were inoculated with scrapie prions, they failed to
develop clinical signs of scrapie, even though they could
be shown to replicate prion infectivity (albeit at lower
levels than wild-type mice) and produce protease-resis-
tant PrPSc. Histological examination of the brains of in-
oculated animals demonstrated a striking accumulation
of extracellular PrP deposits with the characteristics of
amyloid.
How can these unusual findings be explained? One in-
terpretation is that highly polymerized, amyloid forms of
PrP are not intrinsically pathogenic, even though they are
infectious. Thus, infectious and toxic forms of PrP may
have distinct biophysical properties. This conclusion is
consistent with the studies, discussed above, of trans-
genic mice expressing mutant forms of PrP that are path-
ogenic but not infectious (Chiesa et al., 2003; Nazor et al.,
2005). It would be of interest to characterize the size dis-
tribution and biophysical properties of PrPSc found in the
brains of the GPI2 mice, perhaps using the techniques
described by Silveira et al. (2005), to determine whether
large, amyloid polymers predominate at the expense of
smaller, potentially neurotoxic oligomers.
A second possible implication of the study by Chese-
bro et al. is that GPI anchor of PrP somehow plays a role
in the cellular response to prions. In this view, PrPC
would serve as a required transducer of a PrPSc-derived
neurotoxic signal, and the absence of a membrane
anchor on PrPC would prevent generation of this signal.
This hypothesis is consistent with the striking observa-
tion that neurons in the brains of PrP null mice are resis-
tant to the toxic effects of PrPSc supplied from grafted
brain tissue (Brandner et al., 1996) or from nearby astro-
cytes (Mallucci et al., 2003).
Cellular Mechanisms of Prion Toxicity: Loss, Gain,
or Subversion of PrPC Function?
If PrPC transduces neurotoxic signals during prion infec-
tion, what is the normal, physiological function of this
protein? Attempts to answer this question by analyzing
the phenotypes of PrP null mice have been unrewarding,
since lines of these mice in which the gene encoding
Doppel (a PrP paralog) is not artifactually upregulated
display no major anatomical or developmental deficits
(Bu¨eler et al., 1992). A variety of functions have been
proposed for PrPC, including roles in metal ion traffick-
ing, cell adhesion, and signal transduction, but definitive
evidence for any of these possibilities is lacking.
A particularly intriguing hypothesis, and one that may
be relevant to the mechanism of prion toxicity, postu-
lates that PrPC functions as a cytoprotective molecule.
Several experimental results support this idea (see Rou-
cou and LeBlanc, 2005, and references therein). First,
PrP overexpression rescues cultured neurons, some
mammalian cell lines, and yeast (Li and Harris, 2005)
from several kinds of death-inducing stimuli. Second,
there is evidence that endogenous PrP protects cultured
neurons against oxidative stress, and brain tissue
against ischemia or trauma in vivo. In a recently pub-
lished study, PrP was also found to be important for
self-renewal of hematopoietic stem cells during serial
transplantation, a phenomenon that may depend on anantiapoptotic activity of the protein (Zhang et al., 2006).
Finally, coexpression of even subphysiological levels of
wild-type PrP completely abrogates the neurodegenera-
tive phenotypes of mice expressing Doppel or N-termi-
nally truncated forms of PrP (PrPD32-121 and D32-134)
(Behrens and Aguzzi, 2002).
If the normal function of PrPC is neuroprotection, then
loss of this function by conversion to PrPSc might con-
tribute to prion-induced neurodegeneration (Figure 1B).
A loss-of-function mechanism appears to be incompat-
ible with the observation that Prn-p0/0 mice are relatively
normal and do not display features of prion disease
(Bu¨eler et al., 1992). However, a biological activity of
PrPC that is dispensable under normal conditions may
become essential in the disease state due to cellular or
organismal stress.
Another possibility is that PrPSc subverts or modifies
the normal function of PrPC, rather than causing a com-
plete loss of PrPC function (Figure 1C). For example, the
activity of a putative PrPC signaling pathway might be
altered by binding to PrPSc (or to another pathogenic in-
termediate), such that a neurotoxic rather than a neuro-
protective stimulus is delivered. PrPSc might produce
this effect by cross-linking of cell-surface PrPC, which
has been shown to induce apoptosis of CNS neurons
in vivo (Solforosi et al., 2004), or by binding to and block-
ing specific functional domains of PrPC. The neurode-
generative phenotype of transgenic mice expressing
PrPD32-121/134 (Behrens and Aguzzi, 2002) suggests
that specific domains of PrP are essential for its neuro-
protective activity and that deletion of these domains
unmasks a neurotoxic activity, perhaps by altering inter-
action with critical signaling proteins. Binding of PrPSc
to PrPC might produce a similar inversion of PrPC signal-
ing activity.
These two hypotheses stand in contrast to the toxic
gain-of-function mechanism that is usually invoked to
Figure 1. Models for the Cellular Toxicity of PrPSc
(A) Toxic gain-of-function mechanism. PrPSc (or PrPtoxic, a patho-
genic intermediate) possesses a novel neurotoxic activity that is
independent of the normal function of PrPC. (B) Loss-of-function
mechanism. PrPC possesses a normal, physiological activity, in
this case neuroprotection, that is lost upon conversion to PrPSc.
(C) Subversion-of-function mechanism. The normal, neuroprotec-
tive activity of PrPC is subverted by binding to PrPSc (or PrPtoxic).
Cross-hatching of the rectangle representing PrPC indicates
a change in its signaling properties such that a neurotoxic rather
than a neuroprotective signal is delivered. In the absence of the
GPI anchor attaching PrPC to the membrane, no signal would be
delivered and disease would not occur, as was observed in the study
of Chesebro et al. (2005).
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ders, including Alzheimer’s, Huntington’s, and Parkin-
son’s diseases. In these cases, the protein aggregates
that accumulate in the brain are presumed to possess
a novel neurotoxic activity that is independent of the
normal, physiological function of the parent protein (Fig-
ure 1A). For example, PrPSc aggregates may block axo-
nal transport, interfere with synaptic transmission, or
physically damage cellular membranes. Although plausi-
ble in many forms of prion disease, such toxic effects are
difficult to invoke in certain familial cases. In these situa-
tions, the pathogenic mutation has no obvious effect on
the biochemical properties or thermodynamic stability
of PrP, and deposition of protein aggregates is minimal
(Chiesa and Harris, 2001). These cases could result
from a dominant-negative effect of the mutant protein
on some aspect of PrPc function. Thus, it is far from set-
tled whether prion diseases are due to gain, loss, or sub-
version of PrP function, or perhaps to some combination
of these mechanisms. It is also unclear whether the same
mechanism is necessarily responsible for all categories
of prion disease (transmissible, familial, and sporadic).
Conclusions
The prion field has advanced enormously during the
past 25 years. The protein-only nature of prions has be-
come much more firmly established, and it is now quite
difficult to accommodate all the known experimental
facts in a viral theory of transmission. The discovery of
yeast and other fungal prions has demonstrated the
generality of the prion phenomenon and made possible
a number of powerful, new experimental approaches.
The studies described in this review have begun to illu-
minate two previously mysterious subjects: the struc-
ture of prions and how they damage neurons. However,
a number of outstanding issues remain to be resolved.
These include the three-dimensional structure of PrPSc,
the mechanism of the PrPC-PrPSc conversion process,
the identity and cellular action of neurotoxic PrP, the
physiological function of PrPC, and the role of prions in
evolution and other biological processes. In addition,
there is a pressing need for development of more sensi-
tive diagnostic tests and more effective therapeutic
strategies for prion diseases. With the current pace of
research in the field, it seems certain that solutions to
these problems will soon be forthcoming.
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